374899-60-2

Basic information

• Product Name: FMOC-L-NLE(6-OH)-OH
• Synonyms: N-(9-FLUORENYLMETHYLOXYCARBONYL)-6-HYDROXY-L-NORLEUCINE;N-ALPHA-(9-FLUORENYLMETHOXYCARBONYL)-6-HYDROXY-L-NORLEUCINE;N-ALPHA-(9-FLUORENYLMETHYLOXYCARBONYL)-6-HYDROXY-L-NORLEUCINE;N-ALPHA-(9-FLUORENYLMETHOXYCARBONYL)-L-6-HYDROXYNORLEUCINE;N-ALPHA-FMOC-6-HYDROXYNORLEUCINE;(S)-N-ALPHA-FMOC-2-AMINO-6-HYDROXYHEXANOIC ACID;FMOC-L-NLE(6-OH)-OH;FMOC-NLE(6-OH)-OH
• CAS NO: 374899-60-2
• Molecular Formula: C₂₁H₂₃NO₅
• Molecular Weight: 369.41
• Mol File: 374899-60-2.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 619.3±55.0 °C(Predicted)
• Appearance: /
• Density: 1.274±0.06 g/cm3(Predicted)
• PKA: 3.87±0.21(Predicted)
• CAS DataBase Reference: FMOC-L-NLE(6-OH)-OH(CAS DataBase Reference)
• NIST Chemistry Reference: FMOC-L-NLE(6-OH)-OH(374899-60-2)
• EPA Substance Registry System: FMOC-L-NLE(6-OH)-OH(374899-60-2)

Safety Data

• Hazardous Substances Data: 374899-60-2(Hazardous Substances Data)

Upstream product

• 13515-95-2 lysine methyl ester dihydrochloride 
• 6033-32-5 (S)-2-amino-6-hydroxyhexanoic acid 
• 82911-69-1 N-(9H-fluoren-2-ylmethoxycarbonyloxy)succinimide 
• 657-27-2 L-Lysine hydrochloride 
• 139262-23-0 9-fluorenylmethoxycarbonyl-L-alanine hydrochloride 

Downstream Products

• 693-13-0 diisopropyl-carbodiimide 

Relevant articles and documents

Facile synthesis and altered ionization efficiency of diverse N ε-alkyllysine-containing peptides

Protein lysine methylation is a biologically-important posttranslational modification. Given the increased use of alkyllysine-containing peptides to study protein methylation, we describe an efficient solid-phase synthesis to access various alkyllysine-containing peptides. As an exemplary application, we evaluated how ionization efficiency of the alkyllysine peptides affects mass spectrometric analysis.

Peptide compounds and their use as protease substrates

This invention is directed generally to peptide compounds and salts, and particularly to peptide compounds and salts that are useful as protease substrates, such as matrix metalloprotease (“MMP”) substrates. This invention also is directed to methods for making such compounds and salts, as well as amino acids that may, for example, be used in such methods. This invention is further directed to methods for using such compounds and salts to, for example, evaluate the effectiveness of potential protease inhibitors and to detect or monitor a disease associated with protease activity.